SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vivimed Labs soars on inking definitive agreement with Strides Shasun

19 May 2017 Evaluate

Vivimed Labs is currently trading at Rs. 114.95, up by 1.85 points or 1.64% from its previous closing of Rs. 113.10 on the BSE.

The scrip opened at Rs. 114.25 and has touched a high and low of Rs. 117.00 and Rs. 113.75 respectively. So far 88949 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 136.40 on 20-Apr-2017 and a 52 week low of Rs. 68.00 on 09-Aug-2016.

Last one week high and low of the scrip stood at Rs. 122.00 and Rs. 109.00 respectively. The current market cap of the company is Rs. 943.66 crore.

The promoters holding in the company stood at 36.48%, while institutions and non-institutions held 4.68% and 58.85% respectively.

Vivimed Labs has inked a definitive agreement with Strides Shasun to grow its presence in the US finished dosage formulation (FDF) business segment. This 50-50 JV in India, will house the company’s US FDA inspected FDF facility in Alathur, Tamil Nadu, and the 50-50 JV in Singapore will house its current portfolio of ANDAs.

The company believes the JV partnership with Strides Shasun offers its portfolio of products the synergies from Strides Shasun’s existing front end in the US market. This coupled with Vivimed’s product development pipeline for the US offers the JV a strong opportunity to grow its footprint aggressively.

MAP India is the exclusive advisor to Vivimed Labs for the above transaction with Strides Shasun.

Vivimed Labs Share Price

7.26 -0.38 (-4.97%)
21-Apr-2026 15:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.70
Dr. Reddys Lab 1220.00
Cipla 1232.60
Zydus Lifesciences 928.05
Lupin 2305.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×